ESR1 and breast neoplasm: In our study we evaluated T47D, MCF7, MDA-MB-468 and MDA-MB-231 cells, all of which responded in vitro consistently with in vivo observations from primary breast tumours; the ER-positive models had a dampened transcriptional response to LXR ligands compared to ER-negative.